GuidelinesOther guideline
Genito Urinary System and Sex Hormones
Cabergoline Levonorgestrel Intrauterine System Estrogen Testosterone Medroxyprogesterone acetate, Cyproterone acetate Cyproterone, Ethinyl estradiol Darifenacin PDE5-inhibititors Finasteride ATC Code G02CB3 Medicine Cabergoline Indication Prolactinoma, refractory/intolerant to bromocriptine NEMLC Recommendation Approved Review Indicators n/a Date Ratified 23 June 2022 ATC Cod
Levonorgestrel Intrauterine System
Medroxyprogesterone acetate, Cyproterone acetate
Cyproterone, Ethinyl estradiol
| ATC Code | G02CB3 |
| Medicine | Cabergoline |
| Indication | Prolactinoma, refractory/intolerant to bromocriptine |
| NEMLC Recommendation |
Approved |
| Review Indicators | n/a |
| Date Ratified | 23 June 2022 |
| ATC Code | G03AC03 |
| Medicine | Levonorgestrel intrauterine system |
| Indication | Abnormal uterine bleeding (3rd line therapy) |
| NEMLC Recommendation |
Approved - Third line therapy where there has been treatment failure - Prescribed and inserted by a gynaecologist |
| Review Indicators | n/a |
| Date Ratified | 27 September 2018 |
| ATC Code | G03CA |
| Medicine | Oestrogen |
| Indication | Gender Dysphoria – Feminising regimen |
| NEMLC Recommendation | Approved |
| Review Indicators | Evidence, perspectives, and terminology in the gender dysphoria/gender incongruence space is evolving. Work in this area is underway to evaluate recommendations. |
| Date Ratified | 5 December 2019 (Caution added: 27 March 2025) |
| ATC Code | G03BA03 |
| Medicine | Testosterone |
| Indication | Gender Dysphoria – Masculinising regimen |
| NEMLC Recommendation | Approved |
| Review Indicators | Evidence, perspectives, and terminology in the gender dysphoria/gender incongruence space is evolving. Work in this area is underway to evaluate recommendations. |
| Date Ratified | 5 December 2019 (Caution added: 27 March 2025) |
| ATC Code | G03DA02/ G03HA01 |
| Medicine | Medroxyprogesterone acetate OR Cyproterone acetate |
| Indication | Patients with hypersexual behaviour including paraphilias |
| NEMLC Recommendation | Approved - Most affordable agent should be procured If price parity: cyproterone is preferred due to decreased frequency of dosing |
| Review Indicators | - Evidence of harm - Price reduction |
| Date Ratified | 11 April 2019 |
| ATC Code | G03HB01 |
| Medicine | Cyproterone, Ethinyl estradiol |
| Indication | Hirsutism |
| NEMLC Recommendation | Approved |
| Review Indicators | n/a |
| Date Ratified | 20 September 2007 |
| ATC Code | G04BD10 |
| Medicine | Urinary antispasmodics: Darifenacin |
| Indication | Over active bladder (OAB) with symptoms of urinary urgency, frequency and/or urge incontinence |
| NEMLC Recommendation | Not Approved |
| Review Indicators | - Price - New safety/efficacy data |
| Date Ratified | 13 March 2008 |
| ATC Code | G04BE |
| Medicine | PDE5-inhibititors: Sildenafil, Tadalafil, Vardenafil |
| Indication | Persistent pulmonary hypertension in neonates (PPHN) in situations where nitric oxide is not available. |
| NEMLC Recommendation | Approved Approved in all settings where neonates with PPHN are being managed. |
| Review Indicators | - Safety changes. |
| Date Ratified | 27 June 2024 |
| ATC Code | G04BE |
| Medicine | PDE5-inhibititors: Sildenafil, Tadalafil, Vardenafil |
| Indication | Adults with primary arterial hypertension (PAH) WHO Group 1. |
| NEMLC Recommendation | Approved |
| Review Indicators | - New high-quality evidence of a clinically relevant benefit/safety concerns. |
| Date Ratified | 29 August 2024 |
| ATC Code | G04CB01 |
| Medicine | Finasteride |
| Indication | Benign prostatic hyperplasia |
| NEMLC Recommendation | Not Approved |
| Review Indicators | Price |
| Date Ratified | 13 March 2008 |